BCL2 and acute myeloid leukemia: In AML, the use of FMS-like tyrosine kinase 3 (FLT3) inhibitors (such as midostaurin), hypomethylating agents, and B-cell leukemia/lymphoma 2 (BCL2) inhibitors (such as venetoclax) has proven useful, especially in patients with specific mutations or in older age groups [16,17].